Jeremy Levin

Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021

Retrieved on: 
Thursday, June 10, 2021
Research, Medical Supplies, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Bristol Myers Squibb, Life sciences, Companies, Squib, Bristol-Myers Squibb, Industry economics), Monoclonal antibodies, Jeremy Levin

Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2021 on Wednesday, July 28, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2021 on Wednesday, July 28, 2021.
  • ET on July 28, 2021, company executives will review financial results and address inquiries from investors and analysts.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference

Retrieved on: 
Tuesday, March 2, 2021
Other Communications, Communications, Professional services, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Professional Services, Bristol Myers Squibb, Squib, Companies, Life sciences, Monoclonal antibodies, Biotechnology, Bristol-Myers Squibb, Jeremy Levin

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will be webcast on Tuesday, March 9, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will be webcast on Tuesday, March 9, 2021.
  • David Elkins , Executive Vice President, Chief Financial Officer will answer questions about the company at 3 p.m.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020

Retrieved on: 
Thursday, September 17, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Bristol Myers Squibb, Life sciences, Companies, Articles, Squib, Bristol-Myers Squibb, Monoclonal antibodies, Jeremy Levin

Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2020 on Thursday, November 5, 2020.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2020 on Thursday, November 5, 2020.
  • ET on November 5, 2020, company executives will review financial results and will address inquiries from investors and analysts.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

Retrieved on: 
Friday, September 11, 2020
Companies, Takeda Pharmaceutical Company, Business, Israeli Jews, Jeremy Levin

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m.

Key Points: 
  • NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m.
  • A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com .
  • Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicineapproach to develop medicines that transform the lives of patients with rare neurological disorders.
  • Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

Bristol Myers Squibb to Participate in Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference

Retrieved on: 
Thursday, September 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Bristol Myers Squibb, Life sciences, Squib, Companies, Articles, Monoclonal antibodies, Bristol-Myers Squibb, Jeremy Levin

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Morgan Stanleys 18th Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, September 17, 2020.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Morgan Stanleys 18th Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, September 17, 2020.
  • , Chairman and Chief Executive Officer will answer questions about the company at 1:15 p.m. EDT.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference

Retrieved on: 
Wednesday, September 2, 2020
Medical devices, Health, FDA, Clinical trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Life sciences, Squib, Companies, Industries, Bristol-Myers Squibb, Monoclonal antibodies, Jeremy Levin

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Citis 15th Annual BioPharma Virtual Conference, which will be webcast on Tuesday, September 8, 2020.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Citis 15th Annual BioPharma Virtual Conference, which will be webcast on Tuesday, September 8, 2020.
  • Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com .
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

New Book Surveys Biotechnology Thought-Leaders on COVID-19

Retrieved on: 
Monday, June 8, 2020
Life sciences, Articles, Operating systems, Universal Windows Platform apps, Amazon Kindle, Proprietary hardware, Audible, Amazon, Biotechnology, E-book, Biopharmaceutical, Jeremy Levin

This book is the opening chapter in the story of how the biopharmaceutical industry, both large and small companies, rose to battle the COVID-19 virus.

Key Points: 
  • This book is the opening chapter in the story of how the biopharmaceutical industry, both large and small companies, rose to battle the COVID-19 virus.
  • I salute my colleagues throughout the industry, some of whose words are recorded in this book, said Dr. Levin, Chairman and CEO of Ovid Therapeutics Inc. and Chairman of the Biotechnology Innovation Organization (BIO).
  • A free download of Biotechnology in the Time of COVID-19 is available for a limited time on Amazon Kindle worldwide.
  • A paperback on Amazon and an Audible audiobook version of the book will be available the week of June 15.

Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 7, 2020
Literature, Jeremy Levin, Poets, Ancient Romans, Ovid, Neptune

The team at Ovid has continued to execute during these challenging times, said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • The team at Ovid has continued to execute during these challenging times, said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • As such, we expect to report topline data from the pivotal Phase 3 NEPTUNE trial in the fourth quarter of 2020.
  • Based on current assessments of clinical trial site re-openings and continued patient interest, Ovid expects topline results from the Phase 3 NEPTUNE trial in the fourth quarter of 2020.
  • Ovid plans to report data from ENDYMION in conjunction with the results of the Phase 2 ELEKTRA trial expected in the third quarter of 2020.

BIO Summit Accelerates Collaboration Between Government & Industry Leaders in Fight Against COVID-19

Retrieved on: 
Thursday, March 26, 2020
Biotechnology, Health, Science, Research, Practice Management, Life sciences, Articles, Jeremy Levin, Biotechnology, Biotechnology Innovation Organization, Bio, Collaboration, Life sciences, Articles, Jeremy Levin, Biotechnology, Biotechnology Innovation Organization, Bio, Collaboration

The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating COVID-19.

Key Points: 
  • The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating COVID-19.
  • The goal is to minimize redundancies and maximize cooperation and collaboration, noted BIO President and CEO Jim Greenwood.
  • He was appointed by BIOs chairman of the board, Dr. Jeremy Levin, to oversee the organizations efforts to foster collaboration across the biopharmaceutical industry.
  • For Dr. Scangos, Greenwood, and others within BIO, the virtual summit was one step in a broader effort to combat the virus.

Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020

Retrieved on: 
Thursday, March 26, 2020
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Bristol-Myers Squibb, Squib, Life sciences, Biotechnology, Industries, Monoclonal antibodies, Eli Lilly and Company, Chloroarenes, RTT, Jeremy Levin

Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020.

Key Points: 
  • Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020.
  • ET on May 7, 2020, company executives will review financial information and address inquiries from analysts.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .